

ABSTRACT

The present invention relates to an siRNA for inhibiting the expression of the programmed cell death ligand-1 gene, a conjugate thereof and a pharmaceutical composition thereof, and a use thereof. The siRNA comprises a sense strand and an antisense strand. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The sense strand comprises a nucleotide sequence selected from one of the nucleotide sequences as set forth in SEQ ID NOs: 1 to 12 or a nucleotide sequence with no more than 3 base mutations thereto. The antisense strand comprises a nucleotide sequence selected from one of the nucleotide sequences as set forth in SEQ ID NOs: 13 to 24 or a nucleotide sequence with no more than 5 base mutations thereto.

FIG. 2